SCHEMBL23577809

SCHEMBL23577809

CCOC(=O)c1cc([N+](=O)[O-])c(O)cc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
LMNA P02545 3/20 0.54
POLB P06746 3/20 0.54
GALR2 O43603 1/20 0.54
MITF O75030 1/20 0.54
HSP90AA1 P07900 1/20 0.54
HPGD P15428 1/20 0.54
XBP1 P17861 1/20 0.54
CCR6 P51684 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
KMT2A Q03164 2/20 0.43
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9488561 0.88 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL23578314 0.84 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL16352780 0.84 PDGFRB (0.48) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL23578282 0.82 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL22208578 0.81 CA12 (0.54) ALDH1A1SMN1; SMN2LMNANPSR1CA12
SCHEMBL16352801 0.80 GPR35 (0.37) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL26121409 0.79 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL26126282 0.79 PDGFRB (0.64) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL30623191 0.79 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2LMNAPOLBGALR2
SCHEMBL15122891 0.78 PDGFRB (0.45) ALDH1A1SMN1; SMN2LMNAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 EP disclosed
CN-115605476-B Substituted tricyclic compounds 鲁宾有限公司 2024-05-24 CN disclosed
US-20230119316-A1 Substituted Tricyclic Compounds LUPIN LIMITED (IN) 2023-04-20 US disclosed
CN-115605476-A Substituted tricyclic compounds 鲁宾有限公司(IN) 2023-01-13 CN disclosed
EP-4081521-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-11-02 EP disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119316-A1 Substituted Tricyclic Compounds SOS1, RSU1, KSR1 ALDH1A1 3322/4885SMN1; SMN2 619/4885LMNA 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.